Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
Biogen reported the company’s Q3 2020 financial results and stated that R&D would be halted on the experimental multiple sclerosis drug opicinumab.
Dyno Therapeutics announced a licensing and collaboration deal with Roche worth up to $1.8 billion to apply the Cambridge, Mass.-based company’s CapsidMap platform to the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system diseases and liver-directed therapies.
The U.S. National Institutes of Health is launching a clinical trial of a combination of Gilead Sciences’ antiviral drug remdesivir (Vitrakvy) and hyperimmune intravenous immunoglobulin (hIVIG).
Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.
Eli Lilly and Co. has partnered with Amgen Inc. to increase the supply of the Indianapolis-based company’s experimental Covid-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.
Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
Seattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.
AbbVie and I-Mab entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4), which was initially discovered and developed by I-Mab for the treatment of various cancers.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.